1
SOCRA Exam Complete Study Guide Official
Practice Exam Actual Exam 2026/2027 with
Detailed Rationales | Complete Exam-Style
Questions | Pass Guaranteed – A+ Graded
Q1. According to ICH GCP E6(R2), which entity is ultimately responsible for
implementing and maintaining quality assurance and quality control systems at a
clinical trial site?
A. The sponsor's monitoring team
B. The IRB/IEC
C. The investigator [CORRECT]
D. The contract research organization
Correct Answer: C
Rationale: Correct because the investigator is responsible for conducting the trial in
compliance with the protocol, GCP, and applicable regulations, including
implementing and maintaining quality systems at the site level.
Q2. A subject withdraws consent 14 months into a 24-month study. Under the
HIPAA Privacy Rule and FDA regulations, what may the sponsor continue to do
with data already collected?
A. Destroy all previously collected data immediately upon withdrawal
B. Only use data if the subject signs a separate data retention authorization
C. Retain and use previously collected data to maintain study integrity and meet
regulatory obligations [CORRECT]
D. Transfer all data to the IRB for permanent storage
Correct Answer: C
,2
Rationale: Correct because FDA regulations allow retention and use of data
collected prior to withdrawal to preserve study integrity and fulfill regulatory
requirements; subjects cannot have their data "removed" from an already analyzed
dataset.
Q3. An SAE occurs at 2:00 PM on Friday. The investigator must report it to the
sponsor within what timeframe per ICH GCP E6?
A. 24 hours of awareness
B. Immediately, but no later than 24 hours after awareness [CORRECT]
C. Within 7 calendar days
D. Within 15 calendar days
Correct Answer: B
Rationale: Correct because ICH GCP E6 Section 4.11.1 requires the investigator to
report all serious adverse events immediately to the sponsor, not exceeding 24
hours after the investigator becomes aware of the event.
Q4. Which of the following is considered an essential document that must be
maintained at the clinical site per ICH GCP E6 Section 8?
A. The sponsor's internal financial audit report
B. The CRO's employee training records
C. The signed investigator agreement with the sponsor [CORRECT]
**D. The marketing department's advertising strategy documents
Correct Answer: C
Rationale: Correct because the investigator agreement is listed under essential
documents in ICH GCP E6 Section 8.2 and must be maintained at the site to
document the formal relationship between sponsor and investigator.
,3
Q5. During a monitoring visit, the CRA identifies that three subjects' informed
consent forms were signed after the first study procedure was already completed.
What is the most appropriate immediate action?
A. Document the finding and discuss it at the next quarterly site staff meeting
B. Re-consent the subjects at the next scheduled visit
C. Report the protocol deviation to the IRB and sponsor immediately [CORRECT]
D. Exclude the subjects' data from the final analysis
Correct Answer: C
Rationale: Correct because performing study procedures before obtaining informed
consent is a serious protocol deviation and potential human subject protection
violation requiring immediate reporting to both the IRB and sponsor.
Q6. Under 21 CFR 312.62, an investigator must retain study records for how long
after the IND is discontinued?
A. 2 years
B. 5 years
C. 2 years after the date the IND is discontinued or 5 years after the date the study
is completed, whichever is later [CORRECT]
D. 10 years after study completion
Correct Answer: C
Rationale: Correct because 21 CFR 312.62(c) specifies retention of records for 2
years after IND discontinuation or 5 years after study completion, whichever is
longer.
Q7. Which of the following best describes the primary purpose of the Investigator's
Brochure (IB)?
A. To serve as the informed consent document template for subjects
B. To provide a marketing summary for the investigational product
, 4
C. To compile clinical and nonclinical data relevant to the study of the
investigational product in human subjects [CORRECT]
D. To outline the statistical analysis plan for the clinical trial
Correct Answer: C
Rationale: Correct because the IB is defined in ICH GCP E6 Section 7 as a
compilation of clinical and nonclinical data on the investigational product relevant
to its study in human subjects.
Q8. A subject experiences nausea and vomiting requiring overnight hospitalization
during a Phase II trial. The investigator determines the event is unrelated to the
study drug. How should this event be classified and reported?
A. Adverse event only; report at next scheduled visit
B. Adverse event of special interest; report within 7 days
C. Serious adverse event; report to sponsor within 24 hours regardless of causality
[CORRECT]
D. Expected adverse event; document in source only
Correct Answer: C
Rationale: Correct because overnight hospitalization meets the SAE criteria
regardless of causality assessment; the investigator must report all SAEs to the
sponsor within 24 hours per ICH GCP E6.
Q9. In a double-blind, placebo-controlled trial, a subject presents to the emergency
department with a life-threatening allergic reaction. The treating physician needs to
know whether the subject is on active drug. What is the correct procedure?
A. The site coordinator may verbally confirm the subject's assignment to the
treating physician
B. The sponsor must be contacted first before any unblinding occurs
C. The investigator should break the code for that individual subject and document
the reason and date [CORRECT]
SOCRA Exam Complete Study Guide Official
Practice Exam Actual Exam 2026/2027 with
Detailed Rationales | Complete Exam-Style
Questions | Pass Guaranteed – A+ Graded
Q1. According to ICH GCP E6(R2), which entity is ultimately responsible for
implementing and maintaining quality assurance and quality control systems at a
clinical trial site?
A. The sponsor's monitoring team
B. The IRB/IEC
C. The investigator [CORRECT]
D. The contract research organization
Correct Answer: C
Rationale: Correct because the investigator is responsible for conducting the trial in
compliance with the protocol, GCP, and applicable regulations, including
implementing and maintaining quality systems at the site level.
Q2. A subject withdraws consent 14 months into a 24-month study. Under the
HIPAA Privacy Rule and FDA regulations, what may the sponsor continue to do
with data already collected?
A. Destroy all previously collected data immediately upon withdrawal
B. Only use data if the subject signs a separate data retention authorization
C. Retain and use previously collected data to maintain study integrity and meet
regulatory obligations [CORRECT]
D. Transfer all data to the IRB for permanent storage
Correct Answer: C
,2
Rationale: Correct because FDA regulations allow retention and use of data
collected prior to withdrawal to preserve study integrity and fulfill regulatory
requirements; subjects cannot have their data "removed" from an already analyzed
dataset.
Q3. An SAE occurs at 2:00 PM on Friday. The investigator must report it to the
sponsor within what timeframe per ICH GCP E6?
A. 24 hours of awareness
B. Immediately, but no later than 24 hours after awareness [CORRECT]
C. Within 7 calendar days
D. Within 15 calendar days
Correct Answer: B
Rationale: Correct because ICH GCP E6 Section 4.11.1 requires the investigator to
report all serious adverse events immediately to the sponsor, not exceeding 24
hours after the investigator becomes aware of the event.
Q4. Which of the following is considered an essential document that must be
maintained at the clinical site per ICH GCP E6 Section 8?
A. The sponsor's internal financial audit report
B. The CRO's employee training records
C. The signed investigator agreement with the sponsor [CORRECT]
**D. The marketing department's advertising strategy documents
Correct Answer: C
Rationale: Correct because the investigator agreement is listed under essential
documents in ICH GCP E6 Section 8.2 and must be maintained at the site to
document the formal relationship between sponsor and investigator.
,3
Q5. During a monitoring visit, the CRA identifies that three subjects' informed
consent forms were signed after the first study procedure was already completed.
What is the most appropriate immediate action?
A. Document the finding and discuss it at the next quarterly site staff meeting
B. Re-consent the subjects at the next scheduled visit
C. Report the protocol deviation to the IRB and sponsor immediately [CORRECT]
D. Exclude the subjects' data from the final analysis
Correct Answer: C
Rationale: Correct because performing study procedures before obtaining informed
consent is a serious protocol deviation and potential human subject protection
violation requiring immediate reporting to both the IRB and sponsor.
Q6. Under 21 CFR 312.62, an investigator must retain study records for how long
after the IND is discontinued?
A. 2 years
B. 5 years
C. 2 years after the date the IND is discontinued or 5 years after the date the study
is completed, whichever is later [CORRECT]
D. 10 years after study completion
Correct Answer: C
Rationale: Correct because 21 CFR 312.62(c) specifies retention of records for 2
years after IND discontinuation or 5 years after study completion, whichever is
longer.
Q7. Which of the following best describes the primary purpose of the Investigator's
Brochure (IB)?
A. To serve as the informed consent document template for subjects
B. To provide a marketing summary for the investigational product
, 4
C. To compile clinical and nonclinical data relevant to the study of the
investigational product in human subjects [CORRECT]
D. To outline the statistical analysis plan for the clinical trial
Correct Answer: C
Rationale: Correct because the IB is defined in ICH GCP E6 Section 7 as a
compilation of clinical and nonclinical data on the investigational product relevant
to its study in human subjects.
Q8. A subject experiences nausea and vomiting requiring overnight hospitalization
during a Phase II trial. The investigator determines the event is unrelated to the
study drug. How should this event be classified and reported?
A. Adverse event only; report at next scheduled visit
B. Adverse event of special interest; report within 7 days
C. Serious adverse event; report to sponsor within 24 hours regardless of causality
[CORRECT]
D. Expected adverse event; document in source only
Correct Answer: C
Rationale: Correct because overnight hospitalization meets the SAE criteria
regardless of causality assessment; the investigator must report all SAEs to the
sponsor within 24 hours per ICH GCP E6.
Q9. In a double-blind, placebo-controlled trial, a subject presents to the emergency
department with a life-threatening allergic reaction. The treating physician needs to
know whether the subject is on active drug. What is the correct procedure?
A. The site coordinator may verbally confirm the subject's assignment to the
treating physician
B. The sponsor must be contacted first before any unblinding occurs
C. The investigator should break the code for that individual subject and document
the reason and date [CORRECT]
